600
Participants
Start Date
October 9, 2020
Primary Completion Date
October 31, 2032
Study Completion Date
October 31, 2032
Standard of care + chemotherapy
Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)
Standard of care
Surgical excision with external radiotherapy (if applicable)
RECRUITING
Institut Paoli-Calmettes, Marseille
RECRUITING
Centre Eugène Marquis, Rennes
RECRUITING
Centre Henri Becquerel, Rouen
RECRUITING
CHRU Besançon, Besançon
WITHDRAWN
Institut Bergonié, Bordeaux
RECRUITING
Centre François Baclesse, Caen
RECRUITING
Centre Jean Perrin, Clermont-Ferrand
RECRUITING
Centre Georges-François Leclerc, Dijon
WITHDRAWN
CHU Grenoble, Grenoble
RECRUITING
CHU Limoges, Limoges
RECRUITING
Centre Léon Bérard, Lyon
RECRUITING
CHU Marseille, Marseille
RECRUITING
Institut de Cancérologie de Montpellier, Montpellier
RECRUITING
Hôpital Cochin, Paris
RECRUITING
CHU Poitiers, Poitiers
RECRUITING
Institut Godinot, Reims
WITHDRAWN
CHU de SAINT ETIENNE, Saint-Etienne
RECRUITING
Institut de Cancérologie de l'Ouest, Saint-Herblain
RECRUITING
Institut de Cancérologie Strasbourg Europe, Strasbourg
RECRUITING
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse
RECRUITING
Institut de Cancérologie de Lorraine - Centre Alexis Vautrin, Vandœuvre-lès-Nancy
RECRUITING
Centre Antoine Lacassagne, Nice
Institut Claudius Regaud
OTHER